There is a clear demand for novel, neurological treatments. While it’s widely known psychedelics hold enormous therapeutic potential, there are a host of challenges, including dosing and potential side effects for the patient. Our guest this week is Dr Sam Clark, who founded Terran Biosciences to develop a safe, effective portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases.  00:52-04:09: About Terran Biosciences 04:09-06:03: What are the challenges of using psychedelics? 06:03-07:32: Is there still a stigma attached to use of psychedelics?  07:32-11:45: How do psychedelics work on the brain? 11:45-13:44: Why are psychedelics a good treatment? 13:44-16:51: What is Idazoxan XR? 16:51-18:01: How do you make changes to drugs? 18:01-21:19: How did you develop your business model? 21:19-22:40: What are Eplivanserin and Volinanserin? 22:40-24:49: How useful are repurposed drugs? 24:49-29:06: Keeping drugs affordable 29:06-30:31: Dealing with patents 30:31-32:41: What are empathogens? 32:41-33:12: Where is the company at with clinical trials? 33:12-35:45: What is NM-101? 35:45-37:47: How does Terran differ from other companies? 37:47-39:54: Are you looking to cure conditions? 39:54-40:48: Schizophrenia Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter